A Phase 1 Study of S-3304 in Patients With Solid Tumors - Tabular View

Tracking Information
First Received Date ^ICMJE	April 9, 2002
Last Updated Date	June 23, 2005
Start Date ^ICMJE	November 2001
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00033215 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	A Phase 1 Study of S-3304 in Patients With Solid Tumors
Official Title ^ICMJE	A Phase 1 Study of S-3304 in Patients With Solid Tumors
Brief Summary	To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population
Detailed Description
Study Phase	Phase I
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Condition ^ICMJE	Solid Tumors
Intervention ^ICMJE	Drug: S-3304
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Active, not recruiting
Enrollment ^ICMJE	28
Completion Date	October 2003
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion criteria: Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s) Must be able to tolerate oral medication Exclusion criteria Patients with other serious illnesses Patients who are receiving treatments
Gender	Both
Ages	18 Years to 85 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00033215
Responsible Party
Study ID Numbers ^ICMJE	0110P1416
Study Sponsor ^ICMJE	Shionogi
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Shionogi
Verification Date	November 2003
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP